Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7613)
All Articles published online
|
Publishing Process of This Article
|
Dec 21, 2016 (publication date) through Nov 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. World J Gastroenterol 2016; 22(47): 10432-10439 [PMID: 28058024 DOI: 10.3748/wjg.v22.i47.10432] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i47/10432.htm |
| Number | Citing Articles |
| 1 |
George Philip, Freddy Cornillie, J Omoniyi Adedokun, Richard Melsheimer, Paul Rutgeerts, Jean-Frédéric Colombel, Colleen Marano. Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data. Journal of Crohn's and Colitis 2019; 13(10): 1257 doi: 10.1093/ecco-jcc/jjz052
|
| 2 |
Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi. Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study. Gut and Liver 2022; 16(5): 764 doi: 10.5009/gnl210335
|
| 3 |
Liang-Fang Wang, Ping-Run Chen, Si-Ke He, Shi-Hao Duan, Yan Zhang. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review. World Journal of Gastroenterology 2023; 29(29): 4481-4498 doi: 10.3748/wjg.v29.i29.4481
Abstract(647) |
Core Tip(585) |
Full Article(HTML)(3146)
|
Full Article with Cover (PDF)-1082K(107)
|
Full Article (Word)-443K(43)
|
Audio-423K(10)
|
Peer-Review Report-263K(65)
|
Answering Reviewers-51K(59)
|
Supplementary Material-133K(74)
|
Full Article (PDF)-663K(251)
|
Full Article (XML)-417K(70)
|
Times Cited (3)
|
Total Visits (7492)
|
Open
|
| 4 |
G. Trejo, A. Marco-Marqués, S.V. Hernández, M.M. Boscá-Watts. Investigación clínica en 2016: artículos destacados. Enfermedad Inflamatoria Intestinal al Día 2017; 16(3): 106 doi: 10.1016/j.eii.2017.03.002
|
| 5 |
Sebastian Stefanovic, Iris Detrez, Griet Compernolle, Els Brouwers, Nejc Sever, Borut Stabuc, Natasa Smrekar, Tina Kurent, Gregor Novak, Matic Kozelj, Marc Ferrante, Ann Gils, David Drobne. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. European Journal of Gastroenterology & Hepatology 2021; 33(1): 54 doi: 10.1097/MEG.0000000000001843
|
| 6 |
Anne S. Strik, Sophie E. Berends, Ron A. Mathôt, Geert R. D’Haens, Mark Löwenberg. Golimumab for moderate to severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2017; 11(5): 401 doi: 10.1080/17474124.2017.1303376
|
| 7 |
Beatrice Orlandini, Gabriele Dragoni, Angela Variola, Arianna Massella, Siro Bagnoli, Riccardo Campi, Francesca Rogai. Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real‐life experience from two Italian IBD centers. Journal of Digestive Diseases 2018; 19(8): 468 doi: 10.1111/1751-2980.12648
|
| 8 |
Iris Detrez, Ganel Schops, Jolien Lefrère, Sophie Tops, Gert Van Assche, Séverine Vermeire, Wouter Van Moerkercke, Marc Ferrante, Ann Gils. Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information. The AAPS Journal 2019; 21(1) doi: 10.1208/s12248-018-0282-x
|
| 9 |
Shiro Nakamura, Teita Asano, Yoshihito Tanaka, Kanami Sugimoto, Shinichi Yoshigoe, Yasuo Suzuki. Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan. Inflammatory Intestinal Diseases 2022; 7(3-4): 128 doi: 10.1159/000528185
|
| 10 |
Georgina Cunningham, Mark A. Samaan, Peter M. Irving. Golimumab in the treatment of ulcerative colitis. Therapeutic Advances in Gastroenterology 2019; 12 doi: 10.1177/1756284818821266
|
| 11 |
Masahiro Iizuka, Takeshi Etou, Shiho Sagara. Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy. World Journal of Gastroenterology 2022; 28(34): 4959-4972 doi: 10.3748/wjg.v28.i34.4959
|
| 12 |
Carlos Taxonera, Marisa Iborra, Marta Maia Bosca-Watts, Saioa Rubio, Óscar Nantes, Rebeca Higuera, Federico Bertoletti, Pilar Martínez-Montiel, Mónica Sierra-Ausin, Noemí Manceñido, José Lázaro Pérez-Calle, Alicia Algaba, David Olivares, Cristina Alba. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis. Current Medical Research and Opinion 2019; 35(7): 1297 doi: 10.1080/03007995.2019.1579557
|
| 13 |
Jim O’Connell, Cathy Rowan, Roisin Stack, Grace Harkin, Vikrant Parihar, Grace Chan, Niall Breslin, Garret Cullen, Cara Dunne, Laurence Egan, Gavin Harewood, Jan Leyden, Finbar MacCarthy, Padraic MacMathuna, Nasir Mahmud, Susan McKiernan, Deirdre McNamara, Hugh Mulcahy, Frank Murray, Anthony O’Connor, Aoibhlinn O’Toole, Stephen Patchett, Barbara Ryan, Juliette Sheridan, Eoin Slattery, Glen Doherty, David Kevans. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. European Journal of Gastroenterology & Hepatology 2018; 30(9): 1019 doi: 10.1097/MEG.0000000000001177
|
| 14 |
Kathrin Perrig, Niklas Krupka, Sebastian Bruno Ulrich Jordi, Jean-Benoît Rossel, Luc Biedermann, Thomas Greuter, Philipp Schreiner, Stephan R. Vavricka, Pascal Juillerat, Emanuel Burri, Dorothee Zimmermann, Michel H. Maillard, Michael Christian Sulz, Stephan Brand, Gerhard Rogler, Benjamin Misselwitz. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therapeutic Advances in Gastroenterology 2022; 15 doi: 10.1177/17562848221074188
|
| 15 |
Abhinav Vasudevan, Peter R Gibson, Daniel R van Langenberg. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?. World Journal of Gastroenterology 2017; 23(35): 6385-6402 doi: 10.3748/wjg.v23.i35.6385
|
| 16 |
Gabriele Dragoni, Marco Le Grazie, Beatrice Orlandini, Francesca Rogai. Golimumab in inflammatory bowel diseases: present and future scenarios. Clinical Journal of Gastroenterology 2019; 12(1): 1 doi: 10.1007/s12328-018-0906-9
|
| 17 |
Carlos Taxonera, Cristina Rodríguez, Federico Bertoletti, Luís Menchén, Julia Arribas, Mónica Sierra, Lara Arias, Pilar Martínez-Montiel, Alba Juan, Eva Iglesias, Alicia Algaba, Noemí Manceñido, Montserrat Rivero, Manuel Barreiro-de Acosta, Pilar López-Serrano, Federico Argüelles-Arias, Ana Gutierrez, David Busquets, Javier P. Gisbert, David Olivares, Marta Calvo, Cristina Alba. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. Inflammatory Bowel Diseases 2017; 23(8): 1394 doi: 10.1097/MIB.0000000000001144
|
| 18 |
Pablo Olivera, Silvio Danese, Lieven Pouillon, Stefanos Bonovas, Laurent Peyrin-Biroulet. Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. Digestive and Liver Disease 2019; 51(3): 327 doi: 10.1016/j.dld.2018.11.002
|
| 19 |
Carl Eriksson, Isabella Visuri, Lina Vigren, Linda Nilsson, Anders Kärnell, Henrik Hjortswang, Daniel Bergemalm, Sven Almer, Erik Hertervig, Per Karlén, Hans Strid, Jonas Halfvarson. Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scandinavian Journal of Gastroenterology 2021; 56(11): 1304 doi: 10.1080/00365521.2021.1963466
|
| 20 |
Peter Bossuyt, Filip Baert, Francois D’Heygere, Antoine Nakad, Catherine Reenaers, Fernand Fontaine, Denis Franchimont, Olivier Dewit, Philippe Van Hootegem, Stijn Vanden Branden, Guy Lambrecht, Marc Ferrante, Pieter Hindryckx, Elisabeth Macken, Philip Caenepeel, Anne Vijverman, Nicolas de Suray, Joris Dutré, Edouard Louis, Jean-Louis Coenegracths. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort. Inflammatory Bowel Diseases 2019; 25(1): 156 doi: 10.1093/ibd/izy219
|
| 21 |
Humza Awan, Urooj Fatima, Ryan Eaw, Naomi Knox, Laith Alrubaiy. The Efficacy of Currently Licensed Biologics for Treatment of Ulcerative Colitis: A Literature Review. Cureus 2023; doi: 10.7759/cureus.37609
|
| 22 |
Jimmy K Limdi. Golimumab for ulcerative colitis: adding perspective to the pursuit. Frontline Gastroenterology 2018; 9(3): 232 doi: 10.1136/flgastro-2017-100929
|
| 23 |
|
| 24 |
Masahiro Iizuka, Takeshi Etou, Yosuke Shimodaira, Takashi Hatakeyama, Shiho Sagara. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World Journal of Gastroenterology 2021; 27(12): 1194-1212 doi: 10.3748/wjg.v27.i12.1194
|
| 25 |
David Olivares, Cristina Alba, Irene Pérez, Valentín Roales, Enrique Rey, Carlos Taxonera. Differences in the need for adalimumab dose optimization between Crohn�s disease and ulcerative colitis. Revista Española de Enfermedades Digestivas 2019; 111 doi: 10.17235/reed.2019.6148/2018
|
| 26 |
Fabrizio Bossa, Giuseppe Biscaglia, Maria Rosa Valvano, Giuseppe Costantino, Angelo Lauria, Rocco Clemente, Concetta Ferracane, Endrit Shahini, Marco Mendolaro, Laurino Grossi, Silvia Mazzuoli, Antonio Rispo, Giuseppe Pranzo, Ladislava Sebkova, Antonio Tursi, Agnese Miranda, Marta Patturelli, Rocco Spagnuolo, Cristina Ricciardelli, Caterina Sgarro, Pietro Paese, Gaetano Inserra, Alessandro Azzarone, Olga Nardone, Walter Fries, Nello Buccianti, Antonino Carlo Privitera, Maria Beatrice Principi, Maria Cappello, Francesco William Guglielmi, Marco Romano, Gabriele Riegler, Libera Fanigliulo, Raffaele Melina, Angelo Andriulli. Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. Digestive Diseases and Sciences 2020; 65(6): 1767 doi: 10.1007/s10620-019-05904-z
|
| 27 |
Javier P Gisbert, María Chaparro. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020; 14(5): 694 doi: 10.1093/ecco-jcc/jjz195
|
| 28 |
Daisuke Hirayama, Satoshi Motoya, Toshifumi Ashida, Katsuyoshi Ando, Mikihiro Fujiya, Takahiro Ito, Shigeru Furukawa, Atsuo Maemoto, Takehiko Katsurada, Shiro Hinotsu, Noriko Sato, Naomi Mizuno, Yoshiko Ikawa, Hiroshi Nakase. Effectiveness and Factors Associated with Response to Golimumab in Japanese Patients with Ulcerative Colitis in Real Clinical Practice: The Phoenix Study. Inflammatory Intestinal Diseases 2023; 8(3): 115 doi: 10.1159/000533871
|
| 29 |
Ana Teresa Melo, Raquel Campanilho-Marques, João Eurico Fonseca. Golimumab (anti-TNF monoclonal antibody): where we stand today. Human Vaccines & Immunotherapeutics 2021; 17(6): 1586 doi: 10.1080/21645515.2020.1836919
|
| 30 |
Mark A Samaan, Polychronis Pavlidis, Jonathan Digby-Bell, Emma L Johnston, Angad Dhillon, Ramesh Paramsothy, Abisoye O Akintimehin, Lucy Medcalf, Guy Chung-Faye, Patrick DuBois, Ioannis Koumoutsos, Nick Powell, Simon H C Anderson, Jeremy Sanderson, Bu’ Hussain Hayee, Peter M Irving. Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterology 2018; 9(3): 221 doi: 10.1136/flgastro-2017-100895
|